MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients

NCT06237192 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

200

Enrollment

NETWORK

Sponsor class

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions

DRUG: blinatumomab for B-ALL, venetoclax for T-ALL

Sponsor

National Research Center for Hematology, Russia